Important Information Regarding Mounjaro®▼ (tirzepatide) Price Changes

We would like to update our patients and community regarding Mounjaro®▼ (tirzepatide), a treatment manufactured by Eli Lilly & Company. From 1st September 2025, Lilly will be increasing the UK list price of Mounjaro to bring it in line with prices across Europe and other developed countries.

We understand that changes to medication pricing can feel concerning. Our priority is to keep you informed, support you through this transition, and continue to provide the highest standard of care at a fair and transparent cost.

Why is the price of Mounjaro increasing?

Lilly have confirmed that the UK list price will rise from September 2025 following a review of international pricing. When Mounjaro first launched in the UK, it was introduced at a significantly lower cost than the European average, to ensure rapid access for NHS patients during a period of limited supply of GLP-1 RA treatments for type 2 diabetes.

Since then, new clinical evidence has further demonstrated the effectiveness and value of Mounjaro. To ensure fair global contributions to the cost of innovation and ongoing research, the UK list price is now being aligned more closely with that of other developed countries.

Why must the UK price be in line with Europe?

Having a much lower price in the UK compared to other countries creates risks of illegal parallel exporting, where UK supply is redirected abroad for profit. This not only disrupts the supply chain but can also threaten availability for UK patients.

By adjusting the price, Lilly aims to safeguard supply for patients here in the UK and prevent disruption caused by unlawful export activity.

What does this mean for our patients?

While the medication itself remains unchanged, its cost will increase nationwide from September. This applies across all private providers, including clinics, pharmacies, and digital services.

At Ready Health Standish, we have worked hard to absorb as much of the increase as possible and keep our prices fair and accessible. However, from 1st September 2025, we will need to adjust our charges for Mounjaro in line with the manufacturer’s changes.

Supporting you through the change

We know this adjustment may cause concern, but please be assured:

• We remain committed to helping you achieve your health and weight loss goals.
• Our team is available to answer any questions and provide guidance on how best to manage your treatment plan during your follow up consultations.
• We will continue to monitor pricing and supply closely, keeping you updated on any further developments.

Can I switch to Ready Health Standish as my provider?

Yes — if you are currently receiving Mounjaro®▼ (tirzepatide) elsewhere, you are welcome to transfer your care to us. We are now accepting new patients who would like to continue their treatment with a trusted, CQC-registered provider.

To switch:

1. Book a follow-up appointment (£20) with our clinical team. Book now

2. Bring a copy of your current prescription to your appointment so we can safely review your treatment and ensure continuity of care. If you are unable to provide a copy of your current prescription, we will not be able to issue new medication until this has been received.

3. Our team will then support you with your medication, answer any questions, and provide ongoing monitoring to help you get the best possible results.

We aim to make the process as smooth as possible and will work with you to ensure there is no interruption to your treatment.

Medication price changes are outside of our control, but your health journey remains our number one priority. We are grateful for your trust and will continue to provide safe, supportive, and affordable care.

If you would like to discuss your treatment or have any concerns, please contact our team directly — we are here to help.